- Email: [email protected]
Isolated protein from Fasciola sp.; Fasciola hepatica and Fasciola gigantica recombinant cathepsin production for cattle or sheep liver fluke recombinant vaccine construction
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Publications Ltd, Rochdale House, 128 Theobalds Road, London WClX 8RD. Isolated protein from Fasciola sp.; Fasciola hepatica and Fasciola gigantica recombinant catbepsin production for cattle or sheep liver fluke recombinant vaccine construction Daratech
World 9417 820; 18 August 1994 A protein (I) comprising Gln-Xaa-Xaa-Xaa-Xaal-Xaa-CysTrp-Xaa-Xaa-Xaa2 is claimed, where Xaa is any amino acid, Xaal is Gly or Glu and Xaa2 is Ser, Thr, Ala or Gly. (I) is preferably capable of inducing a protective or humoral immune response in a mammal (cattle or sheep) against a helminth and is especially cathepsin (EC 3.4.22.1). The helminth is a trematode, preferably a Fasciola sp., especially Fasciola hepatica or Fasciola gigantica and (I) is preferably isolated from a mature or newly excysted larva of this helminth. The protein sequence of (I) is disclosed. Also claimed are: (1) recombinant (I); (2) an antigenic fragment, derivative or analog of (I); (3) nucleic acid encoding (I) which hybridizes under low stringency conditions to all or part of the disclosed DNA sequence; (4) reduction of spread of a helminth parasite involving administering to a susceptible animal (I); and (5) a recombinant vaccine composition comprising (I) and at least one adjuvant and/or diluent acceptable for veterinary use. 009-95 DNA construct expresses retrovirus gag-derived and rev-like elements from the same promoter; potential vaccine and gene therapy applications British Biotechnol World 9420 621; 15 September 1994 A novel DNA construct (I) comprises a single promoter, a gag-derived sequence from a retrovirus, a rev-like element, an RRE-like element and donor and acceptor elements. These elements are arranged so that the promoter drives expression of the gag-derived sequence and the rev-like element. The contruct does not contain a functional em gene. A DNA construct (II) consisting substantially of rev-like, RRE-like and donor and acceptor elements is also claimed. Also claimed are: a vector encoding (I); mammalian host cells transformed with the vector; a process for preparing proteins encoded at least partly by a gag-derived gene from a complex retrovirus, by expressing (I); proteins prepared by this process and particles comprising the proteins; and antibodies raised against proteins or particles. More specifically, (I) further comprises an antigenic sequence in an open reading frame with the gag gene, preferably inserted within an epitope that is surface-exposed when the gag protein forms particles. When (I) comprises an additional antigenic sequence fused with the gag gene, the proteins expressed by it are useful in vaccines. The system may be used in gene therapy. 010-9s Chimeric immunoligand containing interleukin-2 receptor binding sequence; human recombinant interleukin-2 and antibody constant region fusion protein construction using plasmid pIL-Z/IgGl for e.g. leukemia and automimmune disease therapy and recombinant vaccine Protein Design Labs
USA 5349 053; 20 September 1994 A new chimeric immunoligand (I) comprises: an interleukin-2 (IL-2) ligand (composed of a human IL-2 protein sequence
326
Vaccine 1995 Volume 13 Number 3
Vaccine, Vol. 13. No. 3, p. 326. 1995 Copyright 0 1995 Elsevier Science Ltd Printed in Great Britain. All rights reserved 0264-410)(/%5$10.00+0.00
capable of binding an IL-2 receptor on a B lymphocyte or a T lymphocyte) and an immunoglobulin (Ig) constant region component comprising an Ig constant region domain lacking an Ig variable region domain. The ligand component and the constant region of (I) are in peptide linkage via a hinge region of the constant region and (I) binds an IL-2 receptor through the ligand component. (I) is capable of fixing complement and/or mediating antibody-dependent cell cytotoxicity through the constant region component, due to binding of (I) to the cell surface receptor. Preferably, the constant region is a human IgGl heavy chain constant region, especially a hinge domain, a CH2 domain and chain constant region, especially a hinge domain, a CH2 domain and a CH3 domain. (I) preferably contains an additional C-terminal hydrophilic residue. A pharmaceutical composition containing (I) is also new. (I) is expressed as a fusion protein from plasmid pIL-2/IgGl in Sp2/0-derived 87.20.12 cells and used for lymphoma, leukemia or autoimmune disease therapy or in recombinant vaccine 01 l-95 production, etc. A stabilized live vaccine; varicella-zoster virus attenuation recombinant vaccine construction in MCRd cell culture Handai Microorganisms Res. Ass.
or
Jpn 06234 659; 23 August 1994 A stabilized live vaccine containing a virus component consisting of at least one varicella-zoster virus selected from an attenuated live varicella-zoster virus and an attenuated recombinant varicella-zoster virus and a stabilizer (not Ca2+ or Mg *+ , but gelatin, a gelatin derivative, especially gelatin hydrolyzate) and a chelating agent (EDTA) or its salt. The live vaccine can aid the spread of vaccination. In an example, human diploid fibroblast MRC-5 was grown in Dulbecco’s modified Eagle’s medium at 37°C. Varicella-zoster virus Oka strain was inoculated at a multiplicity of infection of 0.03 to the MCR-5 cell culture and grown at 37°C for 2 days. A virus suspension was prepared. It contained (per litre) 6.4g NaCl, 0.16g KCl, 2.3 g Na,HP0,.12H,O, 0.16g KH,P04, 50g sucrose, 1 g Na-L-glutamate, 2 g gelatin, 25 g gelatin hydrolysate and 0.1 g EDTA-3Na. 012-95 Production of human papillomavirus capsid protein and virus-like particle; by baculovirus vector expression in Spodoptera fvugiperda insect or mammal cell culture and useful for recombinant vaccine development and in disease diagnosis Univ. Rochester
World 9420 137; 15 September 1994 A new method for expressing the capsid protein (I) gene of a human or animal papillomavirus (PV) (preferably a human genital PV (HPV), especially HPV-6, HPV-11, HPV-16, HPV-18, HPV-33, HPV-35, HPV-5 or HPV-8, most especially HPV-11 or HPV-6) in a eukaryote or prokaryote cell comprises: transfecting a cell with a recombinant expression vector containing a PV (I) gene under conditions facilitating gene expression the cell. The vector is preferably a baculovirus (BV) and the (I) is preferably the Ll protein (with a deletion of the pentanucleotide mRNA degradation signal sequence AUUUA) or a fragment of the 1.1 protein. Preferably, the cell is a mammal cell or an insect cell and transfection is effected by infection. Also new are: (1) expressing a HPV (I) or virus-like particle (VLP) by cloning a HPV (I) gene into a BV, cotransfecting insect cells (,Spodopterafrugiperda Sf9 cells) with the vector and Autographa californica nuclear-polyhedrosis virus DNA, recovering the recombinant BV and infecting insect cells with the recombinant BV; (2) the recombinant (I); and (3) a HPV VLP, fragment, capsomer or fragment from the recombinant (I). 013-95
World 9417 820; 18 August 1994 A protein (I) comprising Gln-Xaa-Xaa-Xaa-Xaal-Xaa-CysTrp-Xaa-Xaa-Xaa2 is claimed, where Xaa is any amino acid, Xaal is Gly or Glu and Xaa2 is Ser, Thr, Ala or Gly. (I) is preferably capable of inducing a protective or humoral immune response in a mammal (cattle or sheep) against a helminth and is especially cathepsin (EC 3.4.22.1). The helminth is a trematode, preferably a Fasciola sp., especially Fasciola hepatica or Fasciola gigantica and (I) is preferably isolated from a mature or newly excysted larva of this helminth. The protein sequence of (I) is disclosed. Also claimed are: (1) recombinant (I); (2) an antigenic fragment, derivative or analog of (I); (3) nucleic acid encoding (I) which hybridizes under low stringency conditions to all or part of the disclosed DNA sequence; (4) reduction of spread of a helminth parasite involving administering to a susceptible animal (I); and (5) a recombinant vaccine composition comprising (I) and at least one adjuvant and/or diluent acceptable for veterinary use. 009-95 DNA construct expresses retrovirus gag-derived and rev-like elements from the same promoter; potential vaccine and gene therapy applications British Biotechnol World 9420 621; 15 September 1994 A novel DNA construct (I) comprises a single promoter, a gag-derived sequence from a retrovirus, a rev-like element, an RRE-like element and donor and acceptor elements. These elements are arranged so that the promoter drives expression of the gag-derived sequence and the rev-like element. The contruct does not contain a functional em gene. A DNA construct (II) consisting substantially of rev-like, RRE-like and donor and acceptor elements is also claimed. Also claimed are: a vector encoding (I); mammalian host cells transformed with the vector; a process for preparing proteins encoded at least partly by a gag-derived gene from a complex retrovirus, by expressing (I); proteins prepared by this process and particles comprising the proteins; and antibodies raised against proteins or particles. More specifically, (I) further comprises an antigenic sequence in an open reading frame with the gag gene, preferably inserted within an epitope that is surface-exposed when the gag protein forms particles. When (I) comprises an additional antigenic sequence fused with the gag gene, the proteins expressed by it are useful in vaccines. The system may be used in gene therapy. 010-9s Chimeric immunoligand containing interleukin-2 receptor binding sequence; human recombinant interleukin-2 and antibody constant region fusion protein construction using plasmid pIL-Z/IgGl for e.g. leukemia and automimmune disease therapy and recombinant vaccine Protein Design Labs
USA 5349 053; 20 September 1994 A new chimeric immunoligand (I) comprises: an interleukin-2 (IL-2) ligand (composed of a human IL-2 protein sequence
326
Vaccine 1995 Volume 13 Number 3
Vaccine, Vol. 13. No. 3, p. 326. 1995 Copyright 0 1995 Elsevier Science Ltd Printed in Great Britain. All rights reserved 0264-410)(/%5$10.00+0.00
capable of binding an IL-2 receptor on a B lymphocyte or a T lymphocyte) and an immunoglobulin (Ig) constant region component comprising an Ig constant region domain lacking an Ig variable region domain. The ligand component and the constant region of (I) are in peptide linkage via a hinge region of the constant region and (I) binds an IL-2 receptor through the ligand component. (I) is capable of fixing complement and/or mediating antibody-dependent cell cytotoxicity through the constant region component, due to binding of (I) to the cell surface receptor. Preferably, the constant region is a human IgGl heavy chain constant region, especially a hinge domain, a CH2 domain and chain constant region, especially a hinge domain, a CH2 domain and a CH3 domain. (I) preferably contains an additional C-terminal hydrophilic residue. A pharmaceutical composition containing (I) is also new. (I) is expressed as a fusion protein from plasmid pIL-2/IgGl in Sp2/0-derived 87.20.12 cells and used for lymphoma, leukemia or autoimmune disease therapy or in recombinant vaccine 01 l-95 production, etc. A stabilized live vaccine; varicella-zoster virus attenuation recombinant vaccine construction in MCRd cell culture Handai Microorganisms Res. Ass.
or
Jpn 06234 659; 23 August 1994 A stabilized live vaccine containing a virus component consisting of at least one varicella-zoster virus selected from an attenuated live varicella-zoster virus and an attenuated recombinant varicella-zoster virus and a stabilizer (not Ca2+ or Mg *+ , but gelatin, a gelatin derivative, especially gelatin hydrolyzate) and a chelating agent (EDTA) or its salt. The live vaccine can aid the spread of vaccination. In an example, human diploid fibroblast MRC-5 was grown in Dulbecco’s modified Eagle’s medium at 37°C. Varicella-zoster virus Oka strain was inoculated at a multiplicity of infection of 0.03 to the MCR-5 cell culture and grown at 37°C for 2 days. A virus suspension was prepared. It contained (per litre) 6.4g NaCl, 0.16g KCl, 2.3 g Na,HP0,.12H,O, 0.16g KH,P04, 50g sucrose, 1 g Na-L-glutamate, 2 g gelatin, 25 g gelatin hydrolysate and 0.1 g EDTA-3Na. 012-95 Production of human papillomavirus capsid protein and virus-like particle; by baculovirus vector expression in Spodoptera fvugiperda insect or mammal cell culture and useful for recombinant vaccine development and in disease diagnosis Univ. Rochester
World 9420 137; 15 September 1994 A new method for expressing the capsid protein (I) gene of a human or animal papillomavirus (PV) (preferably a human genital PV (HPV), especially HPV-6, HPV-11, HPV-16, HPV-18, HPV-33, HPV-35, HPV-5 or HPV-8, most especially HPV-11 or HPV-6) in a eukaryote or prokaryote cell comprises: transfecting a cell with a recombinant expression vector containing a PV (I) gene under conditions facilitating gene expression the cell. The vector is preferably a baculovirus (BV) and the (I) is preferably the Ll protein (with a deletion of the pentanucleotide mRNA degradation signal sequence AUUUA) or a fragment of the 1.1 protein. Preferably, the cell is a mammal cell or an insect cell and transfection is effected by infection. Also new are: (1) expressing a HPV (I) or virus-like particle (VLP) by cloning a HPV (I) gene into a BV, cotransfecting insect cells (,Spodopterafrugiperda Sf9 cells) with the vector and Autographa californica nuclear-polyhedrosis virus DNA, recovering the recombinant BV and infecting insect cells with the recombinant BV; (2) the recombinant (I); and (3) a HPV VLP, fragment, capsomer or fragment from the recombinant (I). 013-95